Study design: Evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study

Breast Cancer Research

Volumn 6, Issue 3, 2004, Pages

  Bernstein, Jonine L ^a   Langholz, Bryan ^b   Haile, Robert W ^b   Bernstein, Leslie ^b   Thomas, Duncan C ^b   Stovall, Marilyn ^c   Malone, Kathleen E ^d   Lynch, Charles F ^e   Olsen, Jørgen H ^f   Anton Culver, Hoda ^g   Shore, Roy E ^h   Boice, John D ^i,n   Berkowitz, Gertrud S ^a   Gatti, Richard A ^j   Teitelbaum, Susan L ^a   Smith, Susan A ^c   Rosenstein, Barry S ^a   Børresen Dale, Anne Lise ^k   Concannon, Patrick ^l   Thompson, W Douglas ^m  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l BENAROYA RESEARCH INSTITUTE   (United States)

^m UNIVERSITY OF SOUTHERN MAINE   (United States)

ⁿ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Bilateral breast cancer; Breast cancer susceptibility genes; Counter matching; Gene environment interactions; Radiation dosimetry; Study design

Indexed keywords

AGE; ALLELE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RADIOTHERAPY; CANCER REGISTRY; CASE CONTROL STUDY; DOSIMETRY; ENVIRONMENTAL EXPOSURE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMAGING PHANTOM; PRIMARY TUMOR; PROCESS OPTIMIZATION; RACE DIFFERENCE; RADIATION ABSORPTION; RADIATION EXPOSURE; STUDY DESIGN; ADULT; BREAST TUMOR; CLINICAL TRIAL; COCARCINOGENESIS; COMPARATIVE STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; IMAGE QUALITY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; RADIATION DOSE; RADIATION INJURY; RADIOTHERAPY; REGISTER; SECOND CANCER; SINGLE BLIND PROCEDURE; STATISTICAL MODEL; STATISTICS; TUMOR SUPPRESSOR GENE;

ATM PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; COCARCINOGENESIS; DNA-BINDING PROTEINS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIKELIHOOD FUNCTIONS; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; PHANTOMS, IMAGING; PROTEIN-SERINE-THREONINE KINASES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; REGISTRIES; RESEARCH DESIGN; SINGLE-BLIND METHOD; TUMOR SUPPRESSOR PROTEINS;

EID: 3142733451     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr771     Document Type: Article

References (51)

1. Gatti RA, Becker-Catania S, Chun HH, Sun X, Mitui M, Lai CH, Khanlou N, Babaei M, Cheng R, Clark C, Huo Y, Udar NC, Iyer RK: The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone. Clin Rev Allergy Immunol. 2001, 20: 87-108. 10.1385/CRIAI:20:1:87.
2. Kastan MB, Lim DS, Kim ST, Yang D: ATM - a key determinant of multiple cellular responses to irradiation. Acta Oncol. 2001, 40: 686-688. 10.1080/02841860152619089.
3. Cortez D, Wang Y, Qin J, Elledge SJ: Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science. 1999, 286: 1162-1166. 10.1126/science.286.5442.1162.
4. Gatei M, Scott SP, Filippovitch I, Soronika N, Lavin MF, Weber B, Khanna KK: Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res. 2000, 60: 3299-3304.
5. Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE: Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 2000, 60: 5934-5936.
6. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ: Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA. 2000, 97: 10389-10394. 10.1073/pnas.190030497.
7. Melchionna R, Chen XB, Blasina A, McGowan CH: Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol. 2000, 2: 762-765. 10.1038/35036406.
8. Swift M, Morrell D, Massey RB, Chase CL: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991, 325: 1831-1836.
9. Swift M, Reitnauer PJ, Morrell D, Chase CL: Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987, 316: 1289-1294.
10. Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dork T, Bendix R, Kirk J, Tucker K, McCredie MR, Hopper JL, Sambrook J, Mann GJ, Khanna KK: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 2002, 94: 205-215. 10.1093/jnci/94.3.205.
11. Dork T, Bendix R, Bremer M, Rades D, Klopper K, Nicke M, Skawran B, Hector A, Yamini P, Steinmann D, Weise S, Stuhrmann M, Karstens JH: Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res. 2001, 61: 7608-7615.
12. Teraoka SN, Malone KE, Doody DR, Suter NM, Ostrander EA, Daling JR, Concannon P: Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer. 2001, 92: 479-487. 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G.
13. Spring K, Ahangari F, Scott SP, Waring P, Purdie DM, Chen PC, Hourigan K, Ramsay J, McKinnon PJ, Swift M, Lavin MF: Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat Genet. 2002, 32: 185-190. 10.1038/ng958.
14. Chakraborty R, Little MP, Sankaranarayanan K: Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers. IV. Prediction of risks in relatives of cancer-predisposed individuals. Radiat Res. 1998, 149: 493-507.
15. Hall EJ: Radiation, the two-edged sword: cancer risks at high and low doses. Cancer J. 2000, 6: 343-350.
16. Horn PL, Thompson WD, Schwartz SM: Factors associated with the risk of second primary breast cancer: an analysis of data from the Connecticut Tumor Registry. J Chronic Dis. 1987, 40: 1003-1011. 10.1016/0021-9681(87)90114-7.
17. John EM, Kelsey JL: Radiation and other environmental exposures and breast cancer. Epidemiol Rev. 1993, 15: 157-162.
18. Shore RE, Hildreth N, Woodard E, Dvoretsky P, Hempelmann L, Pasternack B: Breast cancer among women given X-ray therapy for acute postpartum mastitis. J Natl Cancer Inst. 1986, 77: 689-696.
19. Howe GR, McLaughlin J: Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with breast cancer mortality in the atomic bomb survivors study. Radiat Res. 1996, 145: 694-707.
20. Little MP, Boice JD: Comparison of breast cancer incidence in the Massachusetts tuberculosis fluoroscopy cohort and in the Japanese atomic bomb survivors. Radiat Res. 1999, 151: 218-224.
21. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD: Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002, 158: 220-235.
22. Boice JD, Preston D, Davis FG, Monson RR: Frequent chest X-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Radiat Res. 1991, 125: 214-222.
23. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD, Gilbert E: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003, 290: 465-475. 10.1001/jama.290.4.465.
24. Basco VE, Coldman AJ, Elwood JM, Young ME: Radiation dose and second breast cancer. Br J Cancer. 1985, 52: 319-325.
25. 60CO. Int J Radiat Oncol Biol Phys. 1989, 17: 205-210.
26. Fraass BA, Roberson PL, Lichter AS: Dose to the contralateral breast due to primary breast irradiation. Int J Radiat Oncol Biol Phys. 1985, 11: 485-497.
27. Boice JD, Harvey EB, Blettner M, Stovall M, Flannery JT: Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992, 326: 781-785.
28. Begg CB: The search for cancer risk factors: when can we stop looking?. Am J Public Health. 2001, 91: 360-364.
29. Thompson WD: Methodologic perspectives on the study of multiple primary cancers. Yale J Biol Med. 1986, 59: 505-516.
30. Begg CB, Berwick M: A note on the estimation of relative risks of rare genetic susceptibility markers. Cancer Epidemiol Biomarkers Prev. 1997, 6: 99-103.
31. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J: Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med. 1992, 326: 1309-1315.
32. Meadows AT, Strong LC, Li FP, D'Angio GJ, Schweisguth O, Freeman AI, Jenkin RD, Morris-Jones P, Nesbit ME: Bone sarcoma as a second malignant neoplasm in children: influence of radiation and genetic predisposition for the Late Effects Study Group. Cancer. 1980, 46: 2603-2606.
33. Rayner CR, Towers JF, Wilson JS: What is Gorlin's syndrome? The diagnosis and management of the basal cell naevus syndrome, based on a study of thirty-seven patients. Br J Plast Surg. 1977, 30: 62-67.
34. Strong LC: Genetic and environmental interactions. Cancer. 1977, 40: 1861-1866.
35. Wong FL, Boice JD, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, Goldman MB, Seddon JM, Tarbell N, Fraumeni JF, Li FP: Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997, 278: 1262-1267. 10.1001/jama.278.15.1262.
36. Robins JM, Gail MH, Lubin JH: More on 'Biased selection of controls for case-control analyses of cohort studies'. Biometrics. 1986, 42: 293-299.
37. Langholz B, Goldstein L: Risk set sampling in epidemiologic cohort studies. Statist Science. 1996, 11: 35-53. 10.1214/ss/1032209663.
38. Langholz B, Goldstein L: Fitting logistic models using conditional logistic likelihood when there are large strata. Comput Sci Statist. 1997, 29: 551-555.
39. WFR-Aquaplast Corporation. [ http://www.wfr-aquaplast.com ]
40. Bernstein JL, Teraoka S, Haile RW, Borresen-Dale AL, Rosenstein BS, Gatti RA, Diep AT, Jansen L, Atencio DP, Olsen JH, Bernstein L, Teitelbaum SL, Thompson WD, Concannon P: Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat. 2003, 21: 542-550. 10.1002/humu.10206.
41. Andrieu N, Goldstein AM, Thomas DC, Langholz B: Counter-matching in studies of gene-environment interaction: efficiency and feasibility. Am J Epidemiol. 2001, 153: 265-274. 10.1093/aje/153.3.265.
42. Cologne J, Langholz B: Selecting controls for assessing interaction in nested case-control studies. J Epidemiol. 2003, 13: 193-202.
43. Langholz B, Clayton D: Sampling strategies in nested case-control studies. Environ Health Perspect. 1994, 102 (Suppl 8): 47-51.
44. Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA: Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst. 2002, 94: 835-844. 10.1093/jnci/94.11.835.
45. Siemiatycki J, Thomas DC: Biological models and statistical interactions: an example from multistage carcinogenesis. Int J Epidemiol. 1981, 10: 383-387.
46. Clayton D, McKeigue PM: Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet. 2001, 358: 1356-1360. 10.1016/S0140-6736(01)06418-2.
47. Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K, Fraumeni JF: The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta. 2001, 1471: C1-C10. 10.1016/S0304-419X(00)00021-4.
48. Brennan P: Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?. Carcinogenesis. 2002, 23: 381-387. 10.1093/carcin/23.3.381.
49. Thomas DC: Temporal effects and interactions in cancer: implications of carcinogenic models. In Environmental Epidemiology: Risk Assessment. Edited by: Prentice RL, Whittemore AS. 1982, Philadelphia: Society for Industrial and Applied Mathematics, 107-121.
50. Langholz B, Borgan O: Counter-matching: a stratified nested case-control sampling method. Biometrika. 1995, 82: 69-79.
51. Huberman M, Langholz B: Application of the missing-indicator method in matched case-control studies with incomplete data. Am J Epidemiol. 1999, 150: 1340-1345.